In the last trading session, 1.49 million Kintara Therapeutics Inc (NASDAQ:KTRA) shares changed hands as the company’s beta touched 0.91. With the company’s per share price at $0.37 changed hands at $0.04 or 9.88% during last session, the market valuation stood at $0.64M. KTRA’s last price was a discount, traded about -4089.19% off its 52-week high of $15.50. The share price had its 52-week low at $0.32, which suggests the last value was 13.51% up since then. When we look at Kintara Therapeutics Inc’s average trading volume, we note the 10-day average is 1.78 million shares, with the 3-month average coming to 372.72K.
Analysts gave the Kintara Therapeutics Inc (KTRA) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended KTRA as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. Kintara Therapeutics Inc’s EPS for the current quarter is expected to be $Atara Biotherapeutics, Inc..
Kintara Therapeutics Inc (NASDAQ:KTRA) trade information
Instantly KTRA was in green as seen at the end of in last trading. With action -4.46%, the performance over the past five days has been red. The jump to weekly highs of 0.4061 on Friday, 11/17/23 added 9.88% to the stock’s daily price. The company’s shares are showing year-to-date downside of -94.69%, with the 5-day performance at -4.46% in the red. However, in the 30-day time frame, Kintara Therapeutics Inc (NASDAQ:KTRA) is -91.47% down. Looking at the short shares, we see there were 83880.0 shares sold at short interest cover period of 0.61 days.
The consensus price target for the stock as assigned by Wall Street analysts is $14.00, meaning bulls need an upside of 97.36% from its current market value. According to analyst projections, KTRA’s forecast low is $14.00 with $14.00 as the target high. To hit the forecast high, the stock’s price needs a -3683.78% plunge from its current level, while the stock would need to soar -3683.78% for it to hit the projected low.
Kintara Therapeutics Inc (KTRA) estimates and forecasts
Data shows that the Kintara Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -87.31% over the past 6 months, a 95.15% in annual growth rate that is considerably higher than the industry average of 14.90%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 49.09%. The 2023 estimates are for Kintara Therapeutics Inc earnings to increase by 88.67%.
Kintara Therapeutics Inc is expected to release its next quarterly earnings report between February 12 and February 16.
Kintara Therapeutics Inc (NASDAQ:KTRA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.17% of Kintara Therapeutics Inc shares while 3.29% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 3.44%. There are 3.29% institutions holding the Kintara Therapeutics Inc stock share, with Geode Capital Management, LLC the top institutional holder. As of Jun 29, 2023, the company held 0.80% of the shares, roughly 14036.0 KTRA shares worth $56565.0.
State Street Corporation holds the second largest percentage of outstanding shares, with 0.61% or 10721.0 shares worth $43205.0 as of Jun 29, 2023.
Among Mutual Funds, the top two as of May 30, 2023 were Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund. With 9104.0 shares estimated at $29223.0 under it, the former controlled 0.52% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.43% of the shares, roughly 7563.0 shares worth around $30478.0.